治疗放射性抗性甲状腺癌的挑战:全球视角,重点关注拉丁美洲发展中国家
G C Penna1,2, K M A B Rajão3, D C Santana4
1Assistant Professor, Department of Clinical Medicine and Postgraduate Program in Applied Health Sciences, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. gustaocpenna@gmail.com.
Endocrine
|July 30, 2024
概括
管理耐放射性分化甲状腺癌 (DTC) 提出了独特的挑战,特别是在拉丁美洲. 难以获得全身疗法和分子测试,需要在药物定价和监管过程方面紧急讨论利益相关者.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 差异化甲状腺癌 (DTC) 通常具有有利的预后.
- 一小部分DTC患者,特别是转移患者,患有放射性耐药性疾病,显著影响生存率.
- 放射性耐火性DTC的管理是复杂的,在资源有限的环境中存在特定的挑战.
研究的目的:
- 分析治疗转移性放射性耐火的分化甲状腺癌 (DTC) 的独特挑战,重点关注拉丁美洲的发展中国家.
- 讨论关键的治疗方面,包括系统治疗的时间,一线药物选择,分子测试和药物/小组可访问性.
- 突出公共卫生保健系统中患者面临的具体障碍.
主要方法:
- 对放射性耐火DTC的管理挑战进行了全面的分析.
- 介绍了来自作者经验的五个说明性临床案例,以展示这些挑战.
- 讨论治疗和获得护理的有争议的方面.
主要成果:
- 虽然DTC预后通常是优秀的,但放射性耐药性疾病影响大约5%的患者,导致生存率降低.
- 获得必需药物的机会是一个重要的障碍,特别是在公共卫生保健系统内,涉及漫长而困难的过程.
- 有关药品定价,基于证据的定价倡导,临床试验参与和简化监管途径的利益相关者之间的紧急对话至关重要.
结论:
- 需要前性随机试验来确定最佳的第一线全身疗法和放射性耐火DTC分子测试的时间.
- 这份手稿为有关治疗和监测放射性抗性甲状腺癌患者的复杂性,特别是发展中国家的重要讨论和知识传播做出了贡献.
- 解决接入障碍和促进协作努力对于改善患者治疗结果至关重要.
关键词:
卡博桑提尼布 (cabozantinib) 是一种药物.分化甲状腺癌分化甲状腺癌.伦瓦提尼布 (Lenvatinib) 是一种药物.具有放射性耐火性的放射性索拉芬尼布 (Sorafenib) 是一个甲状腺癌是一种癌症.更多相关视频
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
1.7K
03:55Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
513
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
